Clinical Trial Update: R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Rituximab-containing dose-adjusted EPOCH-21 versus a Rituximab-containing mNHL-BFM-90 program with Autologous Stem Cell Transplantation …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Etoposide (Etoposide)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: National Research Center for Hematology, Russia | Conditions: Diffuse Large B-Cell Lymphoma | Phase 3 | Status: UNKNOWN